BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KI Science Park - ECPv6.15.0.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KI Science Park
X-ORIGINAL-URL:https://kisciencepark.kisciencepark.hemsida.eu
X-WR-CALDESC:Events for KI Science Park
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250930T080000
DTEND;TZID=Europe/Stockholm:20250930T093000
DTSTAMP:20260421T071127
CREATED:20250903T211035Z
LAST-MODIFIED:20250925T072429Z
UID:10000171-1759219200-1759224600@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Insight Breakfast with Business Sweden – Global Life Science Outlook
DESCRIPTION:Welcome to Insight Breakfast with Business Sweden\nGlobal Life Science Outlook – Featuring Mexico as a Rising Healthcare Innovation Hub\, with Regional Perspectives from Central America \nJoin a session where Business Sweden will present a global perspective on the life science sector\, highlighting why Mexico\, with complementary insights from Central America\, deserves a place on the international innovation map. \nProgram \n08:00 – 08:15 Breakfast\n08:15 – 08:20 Welcome by KI Science Park\n08:20 – 09:00 Presentations\n09:00 – 09:15 Q&A\n09:15 – 09:30 Networking \nRegister here!\nWe are delighted to welcome Mattias Gäreskog\, PhD\, Invest Lead – Life Science at Business Sweden\, who will share insights into global trends\, Business Sweden’s priorities for 2025\, and how Swedish companies can position themselves for international growth. \nFollowing this\, Ximena Gasca\, Senior Consultant for Mexico\, Central America & the Caribbean at Business Sweden\, will provide insights into the region’s dynamic healthcare and life science landscape – showcasing opportunities\, challenges\, and real-world examples of innovation. Mexico’s healthcare market is valued at over USD 90 billion and continues to grow steadily. The country ranks as the 8th largest exporter of medical devices globally\, hosts more than 500 active clinical trials\, and is experiencing rapid expansion in digital health and biotechnology. \nWhy Mexico? \n\nA collaborative ecosystem where companies\, universities\, and hospitals work together\nGovernment initiatives supporting research and innovation\nA vibrant startup and scale-up culture in medtech\, pharma\, and health tech\nStrategic proximity to the U.S. that facilitates trade and clinical collaboration\nEven amid shifting global dynamics\, Mexico’s healthcare innovation and export strength remain a solid foundation for Swedish companies seeking international growth\n\nWhat You’ll Gain from this session \n\nStrategic insights into Mexico’s market potential\nConnections with key local players and potential partners\nSuccess stories like AstraZeneca\nInspiration to accelerate growth and internationalization\n\nJoin us for an inspiring breakfast session where Business Sweden highlights why Mexico deserves a spot on the global life science map – and what opportunities lie ahead for Swedish innovators. \nWarm Welcome! \n 
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/insight-breakfast-bus/
LOCATION:Innomedicum\,  A Working Lab Cafe  |\, Nanna Svarts Väg 4\, Solna\, 17165\, Sweden
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2025/09/insight-breakfast-bus.jpg
ORGANIZER;CN="KI Science Park":MAILTO:event@kisciencepark.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241112T150000
DTEND;TZID=Europe/Stockholm:20241112T160000
DTSTAMP:20260421T071127
CREATED:20241104T085254Z
LAST-MODIFIED:20241104T085254Z
UID:10000113-1731423600-1731427200@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Unlocking NIH Opportunities
DESCRIPTION:How Swedish Companies can Collaborate with the largest Life Science Research Institute in the World\nJoin Business Sweden and the National Institutes of Health (NIH) for an exclusive webinar to explore how Swedish companies can successfully partner with NIH to drive innovation in the US healthcare ecosystem. This session will provide an overview of NIH’s research funding programs\, strategic partnerships\, and the pathways for Swedish businesses to contribute to and benefit from groundbreaking medical and healthcare research together with NIH \nRegister here! \nKey Takeaways \n\nInsights into NIH as a research and commercialization partner\nUnderstanding NIH’s funding mechanisms and eligibility for international companies\nExamples on successful partnerships and collaboration models with NIH\nReview and next steps on how Swedish companies can work with NIH\n\nAbout \nNational Institute of Health:\nThe National Institutes of Health (NIH) is the primary agency of the US government responsible for biomedical and public health research. It funds and conducts critical research aimed at understanding and improving human health\, while fostering collaborations between government\, academic institutions\, and industry to advance medical science and innovation. \nBusiness Sweden:\nBusiness Sweden is commissioned by the Government and the Swedish industry to help Swedish companies grow global sales and international companies invest and expand in Sweden. \nNovadigm Consulting:\nNovadigm Consulting Group provides a wider range of management consulting services to biotechnology companies.
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/unlocking-nih-opportunities/
LOCATION:Webinar: Microsoft teams
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2024/11/241112-bus-webinarie-nih.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240424T083000
DTEND;TZID=Europe/Stockholm:20240424T110000
DTSTAMP:20260421T071127
CREATED:20240315T135829Z
LAST-MODIFIED:20240409T123208Z
UID:10000069-1713947400-1713956400@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Business Sweden Roadtrip: Business Opportunities in the shift to data driven personalized medicine - Europe
DESCRIPTION:Business Sweden invites you to a breakfast seminar and business discussion presenting their latest report: THE ROAD TO PERSONALISED MEDICINE 2023\nCompanies in all stages of their international expansion are welcome to join this meeting. \nRegister here! \nABOUT\nThe developments in data-driven personalised medicine on a global scale present significant opportunities for Swedish companies. The pace of progress may vary\, but the global trend is towards integrating data-driven approaches to optimise healthcare delivery and outcomes. \nAt this event representatives from Business Sweden will present their latest report where they have looked at the drivers of the shift to data driven personalised medicine in different markets\, and some of the business opportunities it represents for Swedish healthcare companies in Europe. \nJoin to find out more about PeCan in France\, DiGa in Germany\, EHDS\, or European harmonization attempts of Digital Health Technology Assessment\, for example.  \nYou will also hear  about upcoming joint activities in Europe for 2024 and you will have the possibility to book individual discussions about your company’s specific opportunities and pain points on the European markets. \nWe invite companies in all stages of their international expansion to join. Business Sweden is committed to supporting your international expansion\, providing you with the necessary tools\, information\, and network. \nFor questions\, please contact britta.stenson@business-sweden.se \nThis seminar series is made possible through the support of our partners; Karolinska Institutet Science Park\, GoCo Health Innovation City  and LU Innovation.  \nThe events are free of charge but registration in advance is mandatory.
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/business-opportunities-in-the-shift-to-data-driven-personalized-medicine-europe/
LOCATION:Innomedicum\,  A Working Lab Cafe  |\, Nanna Svarts Väg 4\, Solna\, 17165\, Sweden
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2024/03/bus-roadshow-240424.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230912T080000
DTEND;TZID=Europe/Stockholm:20230912T090000
DTSTAMP:20260421T071127
CREATED:20230817T152530Z
LAST-MODIFIED:20230817T152958Z
UID:10000019-1694505600-1694509200@kisciencepark.kisciencepark.hemsida.eu
SUMMARY:Reversed pitching from major Japanese pharma companies
DESCRIPTION:This free webinar will give you a great occasion to learn directly from major Japanese pharma companies about collaboration opportunities. Webinar invitation comes from Business Sweden\, Tokyo \nRegister here! \nJapan is the third largest pharmaceutical market in the world. The market size was 11.8 trillion JPY (Approx.8.9 billion SEK) in FY 2019-20. The Government of Japan has promoted the healthcare industry as an important growth engine under the country’s economic revitalization and growth strategy since 2013. Major Japanese pharmaceutical companies spend between 15% and 25% of their revenue on research and development and are moving to further expand their global operations. To further strengthen their pipelines\, they also invest in strategic alliances such as collaborative research and M&A with overseas companies\, academia. \nThe webinar will be a great opportunity for Swedish life science companies and academia to learn about research priorities and collaboration structures of major Japanese Pharmaceutical companies directly from them. \nBusiness Sweden’s Life Science in Tokyo team will also support with arrangement of one-on-one web meetings. After attending the webinar\, please send your non-confidential materials to Business Sweden Tokyo at Etsuko.yasuda@business-sweden.se indicating the companies you wish to have a follow-up meeting with\, and how your company fits their research priorities.  We will set up MS Teams meetings with those companies who agree to meet. \nSignup: No cost\, No later at 12:00 PM CET on 11th September 2023 \nProgram & the key interest areas of the Japanese Pharma companies \n8:00       Opening Remarks / Magnus Blondell\, Life Science Lead East Asia Pacific\, Business Sweden \n8:05       Japanese companies’ presentations \n\nKyouko Saita\, Ph.D.\, Business Development\, Astellas Pharma Inc.\nYuichi Tominaga\, Ph.D.\, Senior Director\, Global Business Development\, Daichi Sankyo Co.\, Ltd.\nShinobu Mitsuda\, Ph.D.\, Deputy Director\, Sohyaku Innovative Research Division\, Mitsubishi Tanabe Pharma Corporation\nHiroki Fujimoto\, Associate Director\, Business Development\, Otsuka Parmaceutical Co.\, Ltd.\nJun Hidaka\, Vice President\, Head of External Innovation\, External Innovation Department (EXID)\, Sumitomo Pharma Co.\, Ltd.\n\n8:50       Q&A \n9:00       Closing \nThe key interest areas of five Japanese Pharma companies are: \nAstellas Pharma Inc. \nAstellas is interested in cutting-edge science/technology which is leveraged in drug discovery including new biological insights\, platforms\, and modalities across multiple therapeutic areas. \n\nCell and gene therapy programs and technologies for regeneration of eye and other organs\nAAV gene therapy projects and technologies\nPrograms and technologies to modulate mitochondria related pathway\nNovel immuno-oncology programs\nTargeted protein degradation programs and technologies\nNew technologies and modalities for immune regulation\, including immunoregulatory cell therapy\nPrograms and Technologies in other emerging research areas including in vivo cell direct reprogramming\, chronobiology\, engineered phage therapy\n\nDaiichi Sankyo Co.\, Ltd. \nDaiichi Sankyo is interested in disruptive science in the preclinical phase and seeking early-stage technology platform-based opportunities for research collaboration with academia or startups. \nOncology \n\nNovel protein degradation technologies that are based on other than the ubiquitin-proteosome system\nCutting-edge technologies that enable targeting “undruggable” epigenetics-related molecules\nUnique antibodies or binders (e.g. Fab\, scFv) against tumor-associated antigens expressed on tumor\, immune\, or stromal cells that are applicable to antibody therapies and/or cell therapies\n\nCNS  \n\nPsychiatric diseases\n\n\nNovel target and psychiatric disease animal model induced by primary neuroinflammation. It is preferable there are biomarkers suitable to judge the therapeutic potential.\nResearch for endogenous ligand\, receptor\, or pathway which is expected to be involved in abnormal activity of specific brain area causing psychiatric disease. Abnormal activity of specific brain areas reported in patients and reproducibility in rodent models is recommended.\n\n\nNeurodegenerative diseases\n\n\nNovel research on glial cell function which can reveal the relevance of the progression of neurodegenerative diseases. Ideas with high originality regarding neuroinflammation\, cellular metabolism\, and senescence are of particular interest.\nResearch for finding novel therapeutic targets utilizing clinical information regarding prognosis and/or data from clinical trials.\n\nMitsubishi Tanabe Pharma Corporation \n\nDrug seeds realizing precision medicines for ALS\, MELAS\, MSA\, PSP\, FTD and ASD\nDrug seeds for targeted protein degradations or antibody drug conjugates for refractory cancers\nClinical samples\, cell models\, and animal models for above diseases\nTargeted protein degradation technologies regarding tissue specific E3 ligase\nDDS or formulation that enable oral administration of middle-molecular weight compounds\nBiomarkers that can be implemented in clinical trials for above diseases (including by wearable devices)\nMethods to identify interactions between small molecules and intrinsically disordered proteins (IDP) which cannot be isolated and purified (NMR is out of our interest)\n\nOtsuka Pharmaceutical Co.\, Ltd. \nOtsuka is focusing on Psychiatry\, Neurology\, Nephrology therapeutics and others including new MOAs\, modalities and platform technologies for our future drug discovery. \n\nEvolutionary/Innovative Science with drug candidate screening/design/selection system\nSmall molecules\, inhibit protein-protein interaction or work as protein degrader\nmRNA therapeutics with distinct nucleotide technology\nNon-viral gene therapy system\nNew and improve antibody/nucleotide delivery system (e.g. oral and high-volume SQ)\nAny novel modalities/molecules to reduce Amyloid beta oligomers or Synuclein fibrils\nTargeting DDS technology for renal and CNS diseases\n\nSumitomo Pharma Co.\, Ltd. \nSumitomo is exploring opportunities on early stage for Assets and Technologies in CNS and Oncology fields\, and Platform Technologies. \n\nPsychiatry: Drug discovery based on neural circuit pathology\nNeurology: Drug discovery based on molecular pathophysiological mechanisms\nOncology: Novel therapeutic targets or agents targeting context-dependent cancer vulnerabilities\, Novel immunotherapies\nPlatform Technologies: Drug discovery platform\, Drug delivery system\, Novel modality suitable for our focused areas
URL:https://kisciencepark.kisciencepark.hemsida.eu/event/reversed-pitching-from-major-japanese-pharma-companies/
ATTACH;FMTTYPE=image/jpeg:https://kisciencepark.kisciencepark.hemsida.eu/wp-content/uploads/2023/08/230912-bus-webevent-1.jpg
END:VEVENT
END:VCALENDAR